Compare Stocks → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:HARPNASDAQ:HTGM Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$3.41-53.7%$7.49$2.83▼$9.01$201.33M1.49262,041 shs5.50 million shsHARPHarpoon Therapeutics$23.01$22.89$3.11▼$23.21$389.61M2.111.52 million shsN/AHTGMHTG Molecular Diagnostics$6.00$3.50▼$7.95N/A0.99294,806 shs773,040 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-53.67%-56.06%-55.19%-28.36%+0.59%HARPHarpoon Therapeutics0.00%0.00%0.00%+2.77%+290.00%HTGMHTG Molecular Diagnostics0.00%0.00%0.00%0.00%-84.36%Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (Ad)Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More NowMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.5915 of 5 stars3.51.00.04.51.61.70.6HARPHarpoon Therapeutics1.6146 of 5 stars2.20.00.04.71.44.20.0HTGMHTG Molecular DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$36.00955.72% UpsideHARPHarpoon Therapeutics2.33Hold$27.2518.43% UpsideHTGMHTG Molecular DiagnosticsN/AN/AN/AN/ACurrent Analyst RatingsLatest HARP, HTGM, and ABEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.003/26/2024HARPHarpoon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform2/26/2024HARPHarpoon TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$13.00 ➝ $23.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M26.65N/AN/A$0.60 per share5.68HARPHarpoon Therapeutics$37.34M10.43N/AN/A$1.63 per share14.12HTGMHTG Molecular Diagnostics$6.37M0.00N/AN/A$2.44 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)HARPHarpoon Therapeutics-$67.73M-$8.76N/AN/AN/A-81.68%-893.55%-45.98%N/AHTGMHTG Molecular Diagnostics-$21.59MN/A0.00N/AN/A-324.25%45.52%8.93%N/ALatest HARP, HTGM, and ABEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AHARPHarpoon TherapeuticsN/AN/AN/AN/AN/AHTGMHTG Molecular DiagnosticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15HARPHarpoon TherapeuticsN/A1.891.89HTGMHTG Molecular DiagnosticsN/A1.401.30OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%HARPHarpoon Therapeutics74.01%HTGMHTG Molecular Diagnostics19.27%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%HARPHarpoon Therapeutics17.00%HTGMHTG Molecular Diagnostics2.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableHARPHarpoon Therapeutics5316.93 million14.05 millionOptionableHTGMHTG Molecular Diagnostics842.21 million2.16 millionOptionableHARP, HTGM, and ABEO HeadlinesSourceHeadlineHTGMQ HTG Molecular Diagnostics, Inc.seekingalpha.com - March 30 at 3:31 PMHTG Molecular Diagnostics Inc HTGMQmorningstar.com - January 4 at 9:00 PMHTG Molecular Diagnostics Inc (HTGMQ)uk.investing.com - September 26 at 7:27 PMMolecular Diagnostics Virtual Event Series 2016labroots.com - September 4 at 11:22 PMMolecular Diagnostics Market Research Report 2023 Growth, Recent Trends and Forecast to 2028 by Key Playersbenzinga.com - August 26 at 10:23 PMRegulating Molecular Diagnostic Assaysmedscape.com - August 23 at 10:07 PMMolecular Diagnostics Virtual Event Series 2017labroots.com - August 16 at 10:19 PMHTG Molecular stock tanks in wake of Chapter 11 bankruptcy filingmsn.com - June 6 at 4:45 PMWhy Are HTG Molecular Diagnostics Shares Plunging Todayfinance.yahoo.com - June 6 at 4:45 PMWhy Is HTG Molecular Diagnostics (HTGM) Stock Down 42% Today?investorplace.com - June 6 at 10:04 AMHTG to Highlight the Advantages of its Drug Discovery Engine at the 2023 BIO International Conventionfinance.yahoo.com - May 18 at 10:33 AMHTG Highlights the Advantages of Its Drug Discovery Enginefinance.yahoo.com - May 16 at 5:25 PMHTG Molecular Diagnostics, Inc.: HTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlightsfinanznachrichten.de - May 11 at 9:38 AMHTG Molecular Diagnostics Reports First Quarter 2023 Results and Provides Recent Business Highlightsfinance.yahoo.com - May 10 at 6:24 PMHTG Provides Update on Drug Discovery Partnering Initiativefinance.yahoo.com - April 25 at 8:24 AMHC Wainwright & Co. Reiterates HTG Molecular Diagnostics (HTGM) Buy Recommendationmsn.com - April 19 at 3:11 PMHTG Announces Key First Quarter Milestone Achievements for Drug Discoveryfinance.yahoo.com - April 18 at 9:02 AMHTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19finance.yahoo.com - April 6 at 12:40 PMHTG Molecular Diagnostics Full Year 2022 Earnings: EPS Misses Expectationsfinance.yahoo.com - April 2 at 1:06 PMWhy Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarketmsn.com - March 24 at 10:28 AMHTGM HTG Molecular Diagnostics, Inc.seekingalpha.com - January 25 at 3:22 PMHTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Eventfinance.yahoo.com - January 9 at 8:50 AMHTG Molecular Diagnostics expects FY22 revenue above consensusmsn.com - January 6 at 7:38 PMHTG Announces Certain Preliminary 2022 Unaudited Financial Resultsca.finance.yahoo.com - January 6 at 2:35 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideBuy the Dip in Paychex, Inc. for a Pay Check at RetirementApril 2, 2024 11:07 AMView Buy the Dip in Paychex, Inc. for a Pay Check at RetirementAll Headlines Company DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Harpoon TherapeuticsNASDAQ:HARPHarpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.HTG Molecular DiagnosticsNASDAQ:HTGMHTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.